Integra Company profile
About Integra Lifesciences Holdings Corp
Integra LifeSciences Holdings Corporation is a medical technology company. The Company operates through two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS segment consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield and Bactiseal. Its product offering includes CereLink in the Unites States and Europe. The Company’s TT segment focuses on three areas, which include complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment includes brands, such as Integra Dermal Matrices, AmnioExcel, SurgiMend, MicroMatrix and NeuraGen. The Company’s manufacturing and research facilities are located in California, Indiana, Maryland, Massachusetts, New Jersey, Ohio, Puerto Rico, Tennessee, Utah, Canada, China, France, Germany, Ireland and Switzerland.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Integra Lifesciences Holdings Corp revenues increased 12% to $1.54B. Net income increased 26% to $169.1M. Revenues reflect Codman Specialty Surgical segment increase of 15% to $1.03B, Tissue Technologies segment increase of 8% to $517.2M, United States segment increase of 12% to $1.09B, Asia/Pacific segment increase of 16% to $182M, Europe segment increase of 11% to $191.3M.
Equity composition
Common Stock $.01 Par, 03/11, 60M auth., 35,807,000 issd., less 7,299,000 shs. in Treas. @ $288M. Insiders & Strategic Owns 27.72%. 8/95, Company acquired Telios Pharmaceuticals for 3,573,743 shares @ $8.65. 5/98, 1-for-2 reverse stock split.
Latest shares articles



